Skip to content

    Sun Pharmaceutical Industries Limited

    SUNPHARMA
    Healthcare·31 Jan 2026
    Management Summary

    Sun Pharmaceutical Industries Limited reported a strong Q3 FY26, driven by robust sales growth across its India and Global Innovative Medicines segments. The company achieved significant improvements in gross and EBITDA margins, alongside a healthy increase in net profit. Strategic launches like Unloxcyt in the US and Ilumya in India, coupled with plans for generic Semaglutide in India, underscore its focus on expanding its innovative and specialty portfolio, despite some softness in the US generics business.

    Highlights

    9

    • Consolidated sales for Q3 FY26 reached ₹1,54,691 million, marking a 15.1% year-on-year growth.

    • Ex-milestone sales growth stood at 14.7% for the quarter.

    • Gross margin for Q3 FY26 was 81%, an increase from the previous year due to a better product mix.

    • EBITDA for the quarter was ₹49,485 million, up 23.4% year-on-year, with an EBITDA margin of 31.9%.

    • Reported net profit after tax for Q3 FY26 was ₹33,688 million, an increase of 16% year-on-year, with adjusted net profit at ₹35,367 million, up 9.9%.

    • EPS for the quarter was ₹14 per share.

    • India formulations sales grew by 16.2% to ₹49,986 million, accounting for 32.3% of total consolidated sales.

    • Global Innovative Medicines sales increased by 14.3% to US$423 million (ex-milestone growth of 13.2%).

    • R&D investments for Q3 FY26 were ₹8,928 million, representing 5.8% of sales.

    What Changed3

    vs Q1 FY27

    Guidance items6 → 2 (-4)Risks discussed4 → 0 (-4)Q&A highlights8 → 0 (-8)

    Guidance & targets

    2
    CategoryTargetPriority
    R&D
    GL0034 Phase-2b study completion
    12-to-18 months
    		Medium
    Tax Rate
    Effective Tax Rate (ETR)
    25%
    		Medium
    2 min read

    Detailed Narrative

    Sun Pharmaceutical Industries Limited delivered a strong performance in Q3 FY26, with consolidated sales reaching ₹1,54,691 million, a 15.1% increase year-on-year. Excluding milestone income, sales growth was a robust 14.7%. The company reported a gross margin of 81%, an improvement attributed to a favorable product mix. EBITDA for the quarter stood at ₹49,485 million, up 23.4% from Q3 FY25, resulting in an EBITDA margin of 31.9%. Net profit after tax grew by 16% to ₹33,688 million, while adjusted net profit increased by 9.9% to ₹35,367 million, translating to an EPS of ₹14 per share. The effective tax rate for the quarter was 24.3%, higher than 14.7% in Q3 FY25 but comparable to 24.7% in Q2 FY26. For the first nine months of FY26, sales were ₹4,36,604 million, growing 11.3%, with an EBITDA of ₹1,37,772 million, up 19.2%, and an EBITDA margin of 31.4%. The Board declared an interim dividend of ₹11 per share for FY26, an increase from ₹10.5 per share in the previous year.

    Segment-wise, India formulations sales were a key driver, growing 16.2% to ₹49,986 million and contributing 32.3% to consolidated sales. Sun Pharma maintained its No. 1 ranking in the Indian pharmaceuticals market with an 8.4% market share as of December 2025. The company announced the upcoming launch of generic Semaglutide in India, branded as Noveltreat and Sematrinity, for chronic weight management and type 2 diabetes, anticipating a day-one generic launch upon patent expiry. Global Innovative Medicines sales increased by 14.3% to US$423 million, with ex-milestone growth at 13.2%. New launches like Unloxcyt in the US for Advanced Cutaneous Squamous Cell Carcinoma and Ilumya in India have shown encouraging early feedback. The US business, however, saw marginal growth of 0.6% to $477 million, with innovative medicines growth offset by lower sales in the generic business due to increased competition.

    Emerging markets formulations revenues were strong, up 21.6% to US$337 million, with underlying constant currency growth of 13%. Key markets like Romania, South Africa, and Brazil performed well. R&D investments for Q3 FY26 totaled ₹8,928 million, representing 5.8% of sales, with innovative R&D accounting for 30.5% of the total R&D spend. The company filed an sBLA for Ilumya with the US FDA for Psoriatic Arthritis and initiated global Phase-II trials for GL0034 in type-2 diabetes. Management indicated that the Phase-2b study for GL0034 is expected to conclude within 12-18 months.

    During the Q&A, management expressed confidence in their M&A strategy, focusing on tuck-ins for emerging markets and strengthening long-term capabilities, while remaining disciplined on valuations. They clarified that the increased spend on new launches like LEQSELVI and UNLOXCYT would become part of core operating OPEX going forward⏳. While acknowledging the competitive landscape for Semaglutide in India, they expressed excitement about expanding market access. The company's effective tax rate is expected to stabilize around 25% for FY27-28. Management maintained a generally bullish tone, highlighting strong organic growth and strategic pipeline development, despite some areas where they chose not to disclose commercially sensitive information.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.